Form D · Biotechnology
Pervasis Therapeutics Inc
Cambridge, MA · CIK 0001309869
Offering snapshot reported Sep 15, 2009 · SEC filing
- Reported sold
- $10M Offering amount: $17.4M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 31, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 15, 2009 | Initial | $10,003,426 | No comparison | 18 | SEC filing |
| Dec 31, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 30, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 17, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 6, 2004 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $91.9K (estimated)
- Finders' fees
- $15K
- Form D file number
- 021-71452
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Musket Research Associates, Inc. | 30599 | David B. Musket · CRD 1321808 |
Source: Form D, filed Sep 15, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Frederic Chereau | Director, Executive |
| Earl M Collier | Director |
| Elazer R Edelman | Director |
| Robert F Higgins | Director |
| Peter B Hutt | Director |
| Edwin M Kania | Director |
| Robert S Langer | Director |
| Frank Litvack | Director |
| Amir Nashat | Director |
| Helen M Nugent | Executive |
| Yoram Richter | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Kendall Square, Suite B6101
Cambridge, MA, 02139-1663
Cambridge, MA, 02139-1663